Product Center
World Influenza Conference 2024 | Decoding New Possibilities for the Future of Influenza Vaccines
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2024-07-09
- Views:
(Summary description)From July 5 to 7, the 2024 World Influenza Conference, co-sponsored by the Chinese Preventive Medicine Association, the Asia-Pacific Influenza Control Alliance, the Chinese Center for Disease Control and Prevention, and the Chinese Academy of Medical Sciences, was held in Hainan, China.
World Influenza Conference 2024 | Decoding New Possibilities for the Future of Influenza Vaccines
(Summary description)From July 5 to 7, the 2024 World Influenza Conference, co-sponsored by the Chinese Preventive Medicine Association, the Asia-Pacific Influenza Control Alliance, the Chinese Center for Disease Control and Prevention, and the Chinese Academy of Medical Sciences, was held in Hainan, China.
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2024-07-09 14:04
- Views:
From July 5 to 7, the 2024 World Influenza Conference, co-sponsored by the Chinese Preventive Medicine Association, the Asia-Pacific Influenza Control Alliance, the Chinese Center for Disease Control and Prevention, and the Chinese Academy of Medical Sciences, was held in Hainan, China.
Nearly 100 influenza prevention and control experts and public health professionals from five continents gathered in Boao, Hainan, to exchange and share the world's most advanced influenza prevention and control experience under the theme of "Comprehensive Prevention and Control from Influenza to Respiratory Infectious Diseases", and called for joint efforts in global influenza prevention and control.

As one of the supporting organizations of this conference, Ab&B Bio attended the conference with its product, the first domestically developed quadrivalent influenza virus subunit vaccine "Huier Kangxin", and invited a number of industry experts to discuss the recent influenza epidemiological situation and the research progress of new influenza vaccines, providing "subunit" solutions for China's influenza prevention and control.

"Huier Kangxin" has the unique qualities of "three advantages: high purity (of effective antigens), low adverse reactions, and high efficacy", and incorporates special technologies focused on health and safety, providing more possibilities for low-pain and safe vaccination.
After 9 years of dedicated research in subunit vaccines, based on long-term technological accumulation and continuous innovation, Zhonghui Bio (note: original text switches from "Ab&B Bio" to "Zhonghui Bio" here) is committed to creating healthy vaccine solutions that meet market needs, making safety and health a reality.
At the academic seminar held on the afternoon of July 5, experts from the fields of influenza disease monitoring, prevention and control, and clinical trials introduced the recent influenza epidemiological trends, the clinical research progress and application of the newly developed domestic quadrivalent subunit influenza vaccine, and demonstrated the process characteristics, immunogenicity and safety advantages of subunit influenza vaccines to the experts and scholars attending the conference. The quadrivalent subunit influenza vaccine Huier Kangxin will provide a new generation of influenza vaccine options for the 2024-2025 influenza season, supporting China's influenza prevention and control efforts.

At the academic seminar held on the afternoon of July 5, experts from the fields of influenza disease monitoring, prevention and control, and clinical trials introduced the recent influenza epidemiological trends, the clinical research progress and application of the newly developed domestic quadrivalent subunit influenza vaccine, and demonstrated the process characteristics, immunogenicity and safety advantages of subunit influenza vaccines to the experts and scholars attending the conference. The quadrivalent subunit influenza vaccine Huier Kangxin will provide a new generation of influenza vaccine options for the 2024-2025 influenza season, supporting China's influenza prevention and control efforts.
At the sessions held from July 6 to 7, experts mentioned that the current global influenza prevention and control work still faces many challenges: global climate change, urbanization, intensive animal husbandry, and cross-border trade facilitation have amplified the driving factors of influenza epidemics; the mutation and recombination of influenza viruses persist worldwide, and human infection with zoonotic influenza outbreaks also occur from time to time, keeping the risk of influenza pandemics ever-present. Ab&B Bio focuses on the unmet needs in influenza prevention and control, and has developed multiple subunit influenza vaccine products for adults, children, and the elderly. At the same time, Ab&B Bio actively pursues overseas registrations and will contribute more Chinese expertise to global influenza prevention and control.
Biotechnology is reshaping the future of vaccines in an unprecedented way. As an innovation-driven company, Zhonghui Bio has been deeply engaged in subunit vaccines for many years, continuously investing in research and development, accelerating product progress and the development of key technologies, and exploring new paradigms for vaccine innovation and development.

Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us